Recent Finacing
Recent Raise
Olatec Therapeutics is a Phase 2/3 clinical-stage biopharmaceutical company developing oral NLRP3 inhibitors, advancing dapansutrile (OLT1177) and ~60 analogues with a >130-patent portfolio for inflammatory diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Olatec Therapeutics.
